Department of Medicine, Hospital South West Jutland, University Hospital of Southern Denmark, Esbjerg, Denmark.
Department of Regional Health Research, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark.
Int J Chron Obstruct Pulmon Dis. 2022 Feb 22;17:405-414. doi: 10.2147/COPD.S350133. eCollection 2022.
Chronic obstructive pulmonary disease (COPD) affects millions of people worldwide. Obesity is commonly seen concomitantly with COPD. People with COPD have reduced quality of life, reduced physical activity, chronic respiratory symptoms, and may suffer from frequent clinical exacerbations. Liraglutide is a glucagon-like peptide-1 receptor agonist (GLP-1RA) approved for weight loss and treatment of type-2 diabetes mellitus. In addition, liraglutide exerts anti-inflammatory actions by reducing IL-6 and MCP-1 levels. We investigated the effect of liraglutide on pulmonary function in people suffering from obesity and COPD.
In this controlled, double-blind trial, 40 people with obesity and COPD from two outpatient clinics were allocated randomly to receive liraglutide (3.0 mg, s.c.) or placebo (s.c.) for 40 weeks. At baseline and after 4, 20, 40, and 44 weeks, participants underwent pulmonary-function tests, 6-min walking test, and replied to a questionnaire regarding the clinical impact of COPD (COPD assessment test (CAT)-score).
Compared with placebo, liraglutide use resulted in significant weight loss, increased forced vital capacity (FVC) and carbon monoxide diffusion capacity, and improved CAT-score. We found no significant changes in forced expiratory volume in one second (FEV), FEV/FVC, or 6-min walking distance.
In patients suffering from obesity and COPD, 40 weeks of treatment with liraglutide improved some measures of pulmonary function. Our study suggests that liraglutide at 3.0 mg may be appropriate treatment in patients with obesity and COPD.
慢性阻塞性肺疾病（COPD）影响着全球数以百万计的人。肥胖症通常与 COPD 同时发生。COPD 患者的生活质量下降，体力活动减少，慢性呼吸道症状明显，并可能经常发生临床恶化。利拉鲁肽是一种胰高血糖素样肽-1 受体激动剂（GLP-1RA），用于减肥和治疗 2 型糖尿病。此外，利拉鲁肽通过降低 IL-6 和 MCP-1 水平发挥抗炎作用。我们研究了利拉鲁肽对肥胖和 COPD 患者肺功能的影响。
在这项对照、双盲试验中，从两家门诊诊所招募了 40 名肥胖和 COPD 患者，随机分为利拉鲁肽（3.0mg，皮下注射）或安慰剂（皮下注射）组，治疗 40 周。在基线和第 4、20、40 和 44 周时，参与者接受了肺功能测试、6 分钟步行测试，并回答了一份关于 COPD 临床影响的问卷（COPD 评估测试（CAT）评分）。
与安慰剂相比，利拉鲁肽组体重显著减轻，用力肺活量（FVC）和一氧化碳弥散量增加，CAT 评分改善。我们发现 1 秒用力呼气量（FEV）、FEV/FVC 或 6 分钟步行距离没有显著变化。
在肥胖和 COPD 患者中，40 周的利拉鲁肽治疗改善了一些肺功能指标。我们的研究表明，利拉鲁肽 3.0mg 可能是肥胖和 COPD 患者的合适治疗方法。
